Determination by anti-bromodeoxyuridine monoclonal antibody of cells in S phase in the human Y79 retinoblastoma line maintained in an organ culture system: effects of butyric acid.
Using bromodeoxyuridine (BrdU) and an anti-BrdU monoclonal antibody (Mab), the fraction of cells in S phase of the Y79 human retinoblastoma line maintained in an organ culture system was determined. The average labeling index (LI) (S phase cell fraction) was 21.5% after 2-15 days in vitro. The effect of butyric acid, which has been reported by others to inhibit the growth of Y79 retinoblastoma cells, was then evaluated in a similar in vitro system. Following treatment with 2 and 3 mM of butyric acid, extensive necrosis was seen in the cultures, and the LI of the surviving cells was significantly (p less than 0.01) lower (4.1 and 2.9%, respectively) than that of the control cultures (21.1%). Forty-eight hours after removal of butyric acid, the LI of the cultures treated respectively with 2 and 3 mM of butyric acid returned to the control level. Our findings suggest that the effect of butyric acid on the cell kinetics of Y79 retinoblastoma cells may be a reversible blocking effect on the G1 phase of the cell cycle.
Nakagawa
Y
Y
Department of Pathology, University of Virginia School of Medicine, Charlottesville.
Perentes
E
E
D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine / Q000276:immunology*; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002460:Cell Line; D005134:Eye Neoplasms / Q000473:pathology*; D006801:Humans; D007399:Interphase; D009924:Organ Culture Techniques; D012175:Retinoblastoma / Q000473:pathology*
D000911:Antibodies, Monoclonal; D002087:Butyrates; D020148:Butyric Acid; D001973:Bromodeoxyuridine